CluePoints was founded in 2012 and is based in Louvain-La-Neuve, Belgium. The company is improving clinical trials using advanced statistics, artificial intelligence, and machine learning. The company provides risk-based quality management (RBQM) and data quality oversight software. To date, they have over 9,500 platform users, de-risked over 1,600 studies, and detected more than 142,000 issues for its customers, which include many of the top 20 largest pharmaceutical companies.

Transforming trials

Pharmaceutical companies, biotechs and contract research organizations can leverage CluePoints’ comprehensive risk-based quality management and data quality oversight solutions to help make clinical trials more efficient and effective.

There are three ways that RBQM can do this:

· Regulatory compliance – Trials must comply with the rules endorsed by governing health authorities. Quality and safety must be top priorities and non-compliance can have detrimental implications for the integrity of clinical trials and the safety of patients. RBQM provides a framework that can help ensure that trials are conducted following global regulations.

· Operational excellence – RBQM allows for continuous monitoring, allowing organizations to detect early issues and intervene, thus minimizing risks. If these processes were to be standardized there’d be a reduction in human error.

· Cost management – Trials are expensive and require a huge amount of resources. RBQM makes operating trials more efficient and organizations can prioritize tasks and direct resources to where they are most needed.

Demand for cost-efficient clinical trials is increasing, with mounting pressure on CROs to deliver substantial savings – so the need for faster, more efficient software is strong.

New product innovation

Traditional coding systems use synonym lists to match terms from medical records to medical codes. Medical coders spend time assigning codes, often with 85% accuracy. CluePoints uses Intelligent Medical Coding, where suggestions are autonomously created, saving time and increasing accuracies to 99%.

Similarly, CluePoints uses SPOT – the Site Profile and Oversight Tool – a flexible tool to make clinical trials more efficient by reducing the need for site monitoring work. It does this by identifying data anomalies. This allows people to plan site visitations better, and improved risk assessments. SPOT provides long-term consistency and control in site monitoring across resourcing models and therapeutic areas, and was a finalist in the 2024 Citeline Awards.

Investing in the next generation of tech leaders

EQT Healthcare Growth invests with the aim of supporting companies with their mission to deliver positive healthcare outcomes, while EQT Technology Growth seeks to invest in the next generation of technology leaders.

CluePoints is at the intersection of pharma, software, and AI, and EQT, which has 30 years’ experience investing in healthcare and technology, is excited to support the company as it develops and moves into its next stage of growth.

Dr Mark Braganza, Partner in the EQT Healthcare Growth Advisory Team, commented: “We are excited to be partnering with CluePoints and its dynamic leadership team to help it scale and reach its full potential. The Company’s ambition is a perfect match with ours to help enable the development of medical research to deliver more effective, efficient and accessible healthcare.”

Kirk Lepke, Partner in the EQT Growth Advisory Team, added: “CluePoints is a prime example of how data, machine learning, and AI can be leveraged to improve real-world outcomes – in this case, pharmaceutical drug development. The entire EQT platform is behind this investment and ready to support the Company with its continued expansion in RBQM and into growing, adjacent markets.”